Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case

INTRODUCTION: Apalutamide is a new second‐generation anti‐androgen agent approved in 2019 for the treatment of metastatic, castration‐sensitive, and non‐metastatic, castration‐resistant prostate cancer. We herein report a case of apalutamide‐induced interstitial lung disease. CASE PRESENTATION: A 74...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirishima, Fumiaki, Shigematsu, Yoshinori, Kobayashi, Kanao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741/
https://www.ncbi.nlm.nih.gov/pubmed/35509772
http://dx.doi.org/10.1002/iju5.12420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057741/
https://www.ncbi.nlm.nih.gov/pubmed/35509772
http://dx.doi.org/10.1002/iju5.12420

Ejemplares similares